NIX
LOE ApproachingNDATOPICALLOTIONPriority Review
Approved
Mar 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
Priority Review
NIX by GSK is clinical pharmacology: the pharmacokinetics (pk) of florfenicol (table 1) and flunixin (table 2) after subcutaneous injection of florfenicol and flunixin meglumine is described below: image of pharmacokinetic parameters table. Approved for bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and 3 more indications. First approved in 1986.
Drug data last refreshed 9h ago
Mechanism of Action
CLINICAL PHARMACOLOGY: The pharmacokinetics (PK) of florfenicol (Table 1) and flunixin (Table 2) after subcutaneous injection of florfenicol and flunixin meglumine is described below: image of pharmacokinetic parameters table
Worked on NIX at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.